Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
98.25 USD | +1.67% | +1.72% | +5.36% |
12:00am | Aegon Ltd. Appoints Chief Strategy, Transformation and Growth Officer and Member of Executive Committee, Effective November 1, 2024 | CI |
09-13 | Zenas BioPharma Shares Rise in Nasdaq Debut | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 4.29B | 106B | 128B | 128B | 89.23B | |||||
Cash & Securities Segregated | - | - | - | - | - | |||||
Securities Purchased Under Agreements To Resell | 88.22B | 116B | 120B | 114B | 111B | |||||
Securities Borrowed | 107B | 112B | 130B | 133B | 121B | |||||
Accounts Receivable, Total | 52.36B | 94.23B | 161B | 108B | 70.61B | |||||
Other Receivables | 121B | 141B | 107B | 167B | 212B | |||||
Gross Property Plant And Equipment | - | - | - | - | - | |||||
Accumulated Depreciation | - | - | - | - | - | |||||
Net Property Plant And Equipment | 4B | 4.42B | 4.27B | 4.07B | 4.37B | |||||
Goodwill | 7.14B | 11.64B | 16.83B | 16.65B | 16.71B | |||||
Other Intangibles, Total | 2.11B | 4.98B | 8.36B | 7.62B | 7.06B | |||||
Investment In Debt and Equity Securities | 106B | 182B | 183B | 160B | 155B | |||||
Trading Asset Securities, Total | 169B | 181B | 193B | 179B | 205B | |||||
Loans Held For Sale | 12.58B | 12.81B | 13.83B | 14.79B | 15.26B | |||||
Restricted Cash | 32.51B | - | - | - | - | |||||
Other Current Assets, Total | 174B | 133B | 104B | 124B | 163B | |||||
Other Long-Term Assets, Total | 16.12B | 17.32B | 19.22B | 22.91B | 23.87B | |||||
Total Assets | 895B | 1,116B | 1,188B | 1,180B | 1,194B | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 198B | 227B | 229B | 216B | 208B | |||||
Short-Term Borrowings | 101B | 117B | 119B | 121B | 125B | |||||
Current Portion of Long-Term Debt | 22.27B | 26.2B | 17.33B | 25.1B | 31.42B | |||||
Current Portion of Leases | 763M | 841M | 886M | 870M | 913M | |||||
Long-Term Debt | 175B | 193B | 216B | 216B | 242B | |||||
Long-Term Leases | 4.02B | 4.49B | 4.27B | 4.03B | 4.5B | |||||
Trust Preferred Securities (BS) | - | - | - | - | - | |||||
Other Current Liabilities - (Brok / FS / Ins. / REIT Template) | 125B | 131B | 130B | 139B | 141B | |||||
Other Non Current Liabilities | 186B | 313B | 365B | 356B | 341B | |||||
Total Liabilities | 813B | 1,013B | 1,082B | 1,079B | 1,094B | |||||
Preferred Stock Redeemable | 8.52B | 9.25B | 7.75B | 8.75B | 8.75B | |||||
Total Preferred Equity | 8.52B | 9.25B | 7.75B | 8.75B | 8.75B | |||||
Common Stock, Total | 20M | 20M | 20M | 20M | 20M | |||||
Additional Paid In Capital | 23.94B | 25.55B | 28.84B | 29.34B | 29.83B | |||||
Retained Earnings | 70.59B | 78.69B | 89.43B | 94.86B | 98B | |||||
Treasury Stock | -18.73B | -9.77B | -17.5B | -26.58B | -31.14B | |||||
Comprehensive Income and Other | -2.79B | -1.96B | -3.1B | -6.25B | -6.42B | |||||
Total Common Equity | 73.03B | 92.53B | 97.69B | 91.39B | 90.29B | |||||
Minority Interest | 1.15B | 1.37B | 1.16B | 1.09B | 944M | |||||
Total Equity | 82.7B | 103B | 107B | 101B | 99.98B | |||||
Total Liabilities And Equity | 895B | 1,116B | 1,188B | 1,180B | 1,194B | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 1.6B | 1.81B | 1.78B | 1.68B | 1.64B | |||||
ECS Total Common Shares Outstanding | 1.59B | 1.81B | 1.77B | 1.68B | 1.63B | |||||
Book Value / Share | 45.82 | 51.13 | 55.12 | 54.55 | 55.5 | |||||
Tangible Book Value | 63.78B | 75.92B | 72.5B | 67.12B | 66.53B | |||||
Tangible Book Value Per Share | 40.01 | 41.95 | 40.91 | 40.06 | 40.89 | |||||
Tangible Book Value Per Share (As Reported) | 40.01 | 41.95 | 40.91 | 40.06 | 40.89 | |||||
Total Debt | 303B | 342B | 357B | 367B | 404B | |||||
Debt Equivalent of Unfunded Proj. Benefit Obligation | 473M | 349M | 476M | 491M | 553M | |||||
Net Debt | -64.91B | -173B | -213B | -187B | -123B | |||||
Equity Method Investments, Total | 2.36B | 2.41B | 2.21B | 1.93B | 1.92B | |||||
Full Time Employees | 60.43K | 68K | 75K | 82K | 80K |